# Study of Safety and Efficacy of BCL201 and Idelalisib in Patients With FL and MCL

> **NCT02603445** · PHASE1 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 20 (actual)

## Conditions studied

- Follicular Lymphoma, Mantle Cell Lymphoma

## Interventions

- **DRUG:** BCL201
- **DRUG:** Idelalisib

## Key facts

- **NCT ID:** NCT02603445
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-11-16
- **Primary completion:** 2018-07-10
- **Final completion:** 2018-07-10
- **Target enrollment:** 20 (ACTUAL)
- **Last updated:** 2020-02-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02603445

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02603445, "Study of Safety and Efficacy of BCL201 and Idelalisib in Patients With FL and MCL". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT02603445. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*